PX’Therapeutics Licenses RIBOVAX’s SEBVI Technology for the Development and Manufacturing of Fully Human Monoclonal Antibo

GRENOBLE, France--(BUSINESS WIRE)-- PX’Therapeutics SA (PX’T) and ribOvax Biotechnologies SA (Ribovax) have announced that they have entered into a licensing agreement to provide PX’T with access to Ribovax’s patented SEBVI Technology for the discovery and development of antibodies of entirely human origin.

SEBVI Technology utilises Epstein Barr Virus to immortalise and isolate circulating human B cells from the blood of immunocompetent individuals which secrete antigen-specific IgG antibodies. This technology enables the generation of high-affinity fully human antibodies that possess a reduced risk of inducing adverse reactions which are normally associated with non-human Ig epitopes. PX’T intends to use the SEBVI technological platform to offer an expanded range of services in the field of human monoclonal antibody development and production for diagnostic and therapeutic applications.

“We are delighted to have signed this partnership with Ribovax to add SEBVI Technology to our growing service portfolio in the field of therapeutic antibodies”, said Tristan Rousselle, CEO and founder of PX’Therapeutics. “This addition gives us a new strong platform for growth and will significantly enhance and complement our existing set of tools for the development and manufacturing of first-in-class therapeutic antibodies”.

“This agreement reflects Ribovax’s strategy to provide pharma companies with access to fully human therapeutic antibodies. Key to this approach is a privileged partnership with PX’Therapeutics that offer a fully integrated service from isolation and selection of the competent human B cells to the production of clinical lots in human cell lines”, said Mikhail Sazonov, member of the Ribovax Biotechnologies SA Board of Directors. He added: “To ensure a quick technology installation at PX’Therapeutics Ribovax used the professional services of Solid Drug Development SA, an operational consultancy company founded by Ribovax’s previous CEO, Jean-Marc Combette.”

ABOUT PX’Therapeutics SA

PX’Therapeutics is a biopharmaceutical contract research and manufacturing organisation specialising in the development of therapeutic antibodies and recombinant proteins from early research stage up to clinical grade GMP manufacturing. With more than 160 clients in Europe, North America and Japan, PX’Therapeutics has acquired an extensive knowledge in the production of valuable therapeutic candidates.

ABOUT ribOvax Biotechnologies SA :

ribOvax Biotechnologies SA is a privately held company dedicated to the development of innovative antibody technology platforms and products in areas with clearly identified medical needs. Ribovax owns two proprietary technology platforms in the field of antibody engineering that have already delivered patented therapeutic and diagnostic fully human monoclonal antibodies. Ribovax has produced proprietary antibodies in the field of infectious diseases (HSV 1 and 2, CMV, Rubella, VZV) and oncology (anti-Alpha Enolase).



CONTACT:

PX’Therapeutics SA:
Claire Untereiner, Director, Business development
Email: [email protected]
+33 (0)4.38.02.36.50
www.px-therapeutics.com
or
ribOvax Biotechnologies SA:
Michel Sazonov, Director
Email: [email protected]
www.ribovax.com
or
Solid Drug Development SA
Jean-Marc Combette, CEO
Email: [email protected]
www.soliddrugdevelopment.com

KEYWORDS:   United States  Europe  North America  France

INDUSTRY KEYWORDS:   Health  AIDS  Biotechnology  Clinical Trials  Hospitals  Oncology  Pharmaceutical  Research  FDA  Science

MEDIA:

Logo
 Logo

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.